Nucana reports first quarter 2024 financial results and provides business update

Key data readouts on track for all programs in 2024 randomized phase 2 study of 182 second-line colorectal cancer patients fully enrolled nuc-7738 plus pembrolizumab demonstrated encouraging anti-cancer activity in several patients who were resistant to pd-1 inhibitors anticipated cash runway into q1 2025 edinburgh, united kingdom, may 16, 2024 (globe newswire) -- nucana plc (nasdaq: ncna) announced financial results for the first quarter ended march 31, 2024 and provided an update on its broad clinical development program with its transformative protide therapeutics. as of march 31, 2024, nucana had cash and cash equivalents of £12.9 million compared to £17.2 million at december 31, 2023.
NCNA Ratings Summary
NCNA Quant Ranking